Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Lifetime Myeloma Cardiomyopathy Risk
Lifetime Myeloma Cardiomyopathy Risk
Your lifetime myeloma cardiomyopathy risk is growing every year you’ve survived MM, especially if you’ve undergone one of the chemo regimens mentioned in the video below.
While I didn’t undergo any of the common induction chemotherapy regimens used today for newly diagnosed MM patients, I did undergo anthracycline, cyclophosphamide, melphalan, and cytoxan. All mentioned in the video below.
The study below talks about chemotherapy-induced cardiomyopathy and young cancer patients. The issue is how long the patient lives after receiving cardiotoxic chemotherapy.
In my case, I developed chemotherapy-induced cardiomyopathy fully 15 years after my ASCT.
Toxic Cardiomyopathy (Chemotherapy-induced) Explained Causes, Symptoms and Treatment, All Insights
MM survivors are living longer and longer. I believe that MM patients undergo cardiotoxic chemo, and therefore, a growing number of MM survivors will develop CIC in the future. I believe that my heart-healthy nutrition, supplementation and lifestyle therapies helped me hold off heart damage.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing CIC with evidence-based non-conventional therapies.
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association
Abstract
The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward.
Anthracycline chemotherapy and chest-directed radiotherapy are the most well-studied cardiotoxic therapies, and
- dose reduction,
- use of cardioprotection for anthracyclines,
- and modern radiotherapy
approaches have contributed to improved cardiovascular outcomes for survivors. Newer treatments such as small-molecule inhibitors, antibody-based cytotoxic therapy, and immunotherapy have expanded options for previously difficult-to-treat cancers but have also revealed new cardiotoxic profiles.
Application of effective surveillance strategies in patients with cancer and survivors has been a focus of practitioners and researchers, whereas the prevention and treatment of extant cardiovascular disease is still developing. Incorporation of new strategies in an equitable manner and appropriate transition from pediatric to adult care will greatly influence long-term health-related outcomes in the growing population of childhood cancer survivors at risk for cardiovascular disease…
Future Directions
During the past 4 decades, a growing body of literature has characterized the epidemiology of CVD in patients with cancer and survivors, identified associations between treatment exposures and resultant cardiovascular complications, and highlighted important modifiers of CVD risk.
This has allowed the development of risk-based screening and intervention recommendations for CVD and cardiovascular risk factors that differ from those established for the general population because risk scores developed for the general population do not take into consideration unique treatment-related exposures in childhood cancer survivors.129,196,197
Risk-based screening has facilitated consideration of secondary prevention trials to reduce the burden of CVD. However, these CVD prevention trials have focused largely on broad clinical risk groups (eg, history of transient LV dysfunction,180 high-dose [≥250 mg/m2] cumulative anthracycline exposure183), providing mixed results to date.
Recent studies have highlighted the prognostic role of NT-proBNP (N-terminal pro-B-type natriuretic peptide) in refining heart failure risk determination in asymptomatic survivors,108,127 and this may provide the impetus to consider combined clinical and biomarker-based (imaging, blood) approaches to screen for survivors who may derive the most benefit from future secondary prevention efforts.
There have been parallel efforts to further refine CVD risk before the initiation of cardiotoxic therapy, driven largely by studies focusing on germline genomics.53Although these studies initially focused on candidate genes, they have expanded to include customized arrays and genome-wide approaches, providing insights into the pathogenesis of cardiotoxicity associated with chemotherapies such as anthracyclines.53 There are ongoing efforts to integrate findings from these genomic studies with transcriptomics, proteomics, and metabolomics, which would allow more precise risk determination, facilitate the development novel blood biomarkers, and identify therapeutic targets.53 Investigators may also need to consider the role of acquired somatic mutations (eg, clonal hematopoiesis of indeterminate potential) associated with CVD in nononcology populations given the higher prevalence of clonal hematopoiesis of indeterminate potential in childhood cancer survivors compared with community control subjects.198
The success of these efforts will be strengthened by continued transdisciplinary collaborations and a steadfast commitment to bench-to-bedside translation. The emergence of specialized pediatric cardio-oncology clinics199,200 may provide the means to translate these findings, allowing optimization of cardiovascular health outcomes across the cancer care delivery continuum.”
Lifetime Myeloma Cardiomyopathy Risk Lifetime Myeloma Cardiomyopathy Risk